Roberto Alejandro Sica

https://assets.montefioreeinstein.org/profiles/images/physphoto/Sica_Roberto_Alejandro_MD_420x504.jpg

First Name

Roberto Alejandro

Last Name

Sica

NPI

1316133648

Faculty ID

15943

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Male

Email

Phone

Titles

Locations

Education and Trainings

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Clinical Focus

Dr. Sica’s clinical focus has been on chimeric antigen receptor (CAR) T-cell therapies, immunotherapies and allogeneic stem cell transplantation, central nervous system (CNS) lymphomas and HIV, ATLL and gene therapy for malignant and nonmalignant hematologic disorders.

Research Focus

Dr. Sica’s research focuses on novel cellular therapies, allogeneic bone marrow transplantation for malignant and nonmalignant hematologic disorders, and combination immunotherapy and cancer vaccine.

Elsevier Profile

EMR ID

15901

Biography

<p>Roberto Alejandro Sica, MD, is an Attending Physician at Montefiore and an Assistant Professor of Medicine at our Albert Einstein College of Medicine. Since joining the Montefiore team, Dr. Sica&rsquo;s clinical focus has been on chimeric antigen receptor (CAR) T-cell therapies, immunotherapies and allogeneic stem cell transplantation, central nervous system (CNS) lymphomas and HIV, ATLL and gene therapy for malignant and nonmalignant hematologic disorders. Dr. Sica is a member of the Bone Marrow Transplant team at Montefiore.</p><p>Dr. Sica attended the University of Buenos Aires School of Medicine, where he received his Medical Degree. During his time there, he also served as an instructor of immunology, virology, pharmacology, and physical diagnosis. Dr. Sica began his postgraduate training with a residency in Internal Medicine at the Carney Hospital/Tufts University School of Medicine in Boston. Following this, he completed a fellowship in Hematology/Oncology at the University of Illinois at Chicago, where he received the E. Donnall Thomas Achievement in Medicine Award for his academic performance and the Edward Jenner Innovation in Medicine Award in recognition of his innovative contributions to the design of clinical protocols and trials. Later, he completed a fellowship in Blood and Marrow Transplant and Cellular Therapies at Stanford University. At that institution, he performed research with Dr. Sally Arai on Hodgkin's lymphoma using the Stanford-pioneered GN-BVC regimen (Gemcitabine, Vinorelbine-BCNU. Etoposide and Cyclophosphamide) which resulted in decreased toxicity and improved overall survival in patients. His work has been published in various review journals and abstracts.</p><p>Dr. Sica&rsquo;s research focuses on novel cellular therapies, allogeneic bone marrow transplantation for malignant and nonmalignant hematologic disorders, and combination immunotherapy and cancer vaccine.</p><p>Dr. Sica is board certified in Internal Medicine, Hematology and Medical Oncology by the American Board of Internal Medicine.</p>

Is Open Scheduling

Off

Amy Sharma

https://assets.montefioreeinstein.org/profiles/images/Sharma_Amy_MD_2x.jpg

First Name

Amy

Last Name

Sharma

NPI

1609178706

Faculty ID

17319

CMO Specialties

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Female

Email

Phone

Titles

Locations

Education and Trainings

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Elsevier Profile

EMR ID

57148

Biography

<p>Amy Sharma , MD, is Co-Director, Hematology Oncology Fellowship Program and Assistant Professor, Hematology Oncology at Montefiore Einstein. Dr. Sharma maintains an active practice focusing on the treatment of sickle cell disease and classical hematology.</p><p>After obtaining her Bachelor of Arts Biology from Cornell University in 2003, Dr. Sharma earned her Doctor of Medicine at the State University of New York at Buffalo in 2007. Following this, she came to Montefiore Einstein to complete her internal medicine residency in 2010 and a hematology oncology fellowship in 2013.</p><p>Dr. Sharma is board certified in Internal Medicine, Hematology and Oncology. She is a member of the American Society of Hematology. From 2015 to 2017, Dr. Sharma was named in <em>SuperDoctors</em> New York Rising Stars. She is fluent in Spanish.</p>

Is Open Scheduling

Off

Nishi N. Shah

https://documentapi-fargate-documentbucket-15qi4tpdvnhlz.s3.amazonaws.com/218/0f80b160-7e92-11ec-9d5a-db3fba8c54fb.jpg

First Name

Nishi

Last Name

Shah

NPI

1467871756

Faculty ID

17086

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Female

Email

Phone

Titles

Locations

Education and Trainings

Research Areas

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Elsevier Profile

PubMed.gov URL

EMR ID

2472

Biography

<p>Nishi Shah, MD, MPH, is an attending physician, Oncology, and Assistant Professor at Montefiore-Einstein. Her clinical focus is on the treatment of patients with hematologic malignancies, with particular focus in plasma cell disorders and B-cell malignancies. She utilizes novel targeted agents, stem cell transplant and cell therapies in the treatment of patients.
</p><p>After earning her medical degree at Grand Medical College in Mumbai, India in 2011, Dr. Shah attended the Rollins School of Public Health at Emory University, earning her Master of Public Health in 2014. She then pursued postgraduate training at University of Arkansas for Medical Sciences, completing her internal medicine internship in 2015 and her internal medicine residency in 2017. She then came to Montefiore to pursue a hematology-oncology fellowship, completing it in 2020.
</p><p>Dr. Shah&rsquo;s research focuses on improving access to care and addressing gaps in health equity for patients with hematologic malignancies as well as exploring methods to improve patient access to clinical trials. She has shared her work through peer-reviewed journals, abstracts, and poster presentations. Dr. Shah is also an ad hoc reviewer for several journals including Acta Hematologica, Leukemia and Lymphoma, and Clinical Lymphoma, Myeloma and Leukemia.
</p><p>Dr. Shah is board certified in hematology and medical oncology, and is a member of several professional societies including the American Society of Hematology, the American Society of Clinical Oncology and the Society for Immunotherapy of Cancer. In 2020, she received the Conquer Cancer Merit Award from the American Society of Clinical Oncology.
</p>

Is Open Scheduling

Off

Yvonne M. Saenger

https://documentapi-fargate-documentbucket-15qi4tpdvnhlz.s3.amazonaws.com/218/5da83a20-2f18-11ed-9b6c-217aa43c9197.jpg

First Name

Yvonne

Last Name

Saenger

NPI

1235363664

Faculty ID

17090

CMO Specialties

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Female

Email

Phone

Titles

Locations

Education and Trainings

Professional Interests

<p>Dr. Yvonne Saenger is an expert in cancer immunotherapy with a focus on melanoma and gastro-intestinal tumors</p>
<p>The Saenger laboratory researches immune biomarkers for melanoma recurrence to stratify patients for adjuvant immunotherapy.&nbsp; Digital pathology and artificial intelligence methods are used.</p>
<p>A second area of focus is analysis of the tumor immune micro-environment in liver cancer, particularly on studying human specimens and organoids to define the role of immune cell populations and complement in tumor progression.</p>

Research Areas

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Elsevier Profile

Selected Publications

<p class="desc" style="margin: 0in 2pt 0in 0in; background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;"><span style="font-size: 14pt; font-family: Calibri, sans-serif; background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;">Gartrell-Corrado RD, Chen A, Rizk EM , Marks DK, Bogardus M, Hart TD, Silverman AM, Bayan CA, Finkel G, Barker L , Komatsubara KM, Carvajal RD, Horst BA, Chang R, Monod A , Rabad&aacute;n R, <strong>Saenger Y</strong>, &ldquo;Linking transcriptomic and imaging data </span><span style="font-size: 14pt; font-family: Calibri, sans-serif; background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;">defines features of a favorable tumor immune microenvironment and identifies a combination biomarker for primary melanoma,&rdquo; <em>Cancer Research.</em> 2020 Mar 1;80(5):1078-1087. PMID:&nbsp;31948941</span></p>
<p class="desc" style="margin: 0in 2pt 0in 0in; background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;"><span style="font-size: 14pt; font-family: Calibri, sans-serif; background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;">&nbsp;</span></p>
<p class="desc" style="margin: 0in 2pt 0in 0in; background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;"><span style="font-size: 14pt; font-family: Calibri, sans-serif; background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;">Kulkarni PM, Robinson EJ, Pradhan JS, Gartrell-Corrado RD, Rohr B, Kluger HM, Wong PF, Acs B, Rizk EM, Yanc C, Mondal M, Moore M, Phelps R, Hoorst BA, Ferringer T, Rimm DL, Wang J, <strong>Saenger Y</strong>, &ldquo;Deep learning based on standard H&amp;E images of primary melanoma tumors identifies patients at risk for visceral recurrence and death,&rdquo; <em>Clinical Cancer Research</em></span><span style="font-size: 14pt; font-family: Calibri, sans-serif;">. 2019 Oct 21. <em>Clinical Cancer Research</em>.1495.2019. PMID: 31636101</span></p>
<p class="desc" style="margin: 0in 2pt 0in 0in; background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;"><span style="font-size: 14.0pt; font-family: 'Calibri',sans-serif; mso-ascii-theme-font: minor-latin; mso-hansi-theme-font: minor-latin; mso-bidi-theme-font: minor-latin;">&nbsp;</span></p>
<p class="desc" style="margin: 0in 2pt 0in 0in; background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;"><span style="font-size: 14pt; font-family: Calibri, sans-serif;">Gartrell RD, Marks DK, Rizk EM, Bogardus M, Gerard CL, Barker LW, Fu Y, Esancy CL, Li G, Ji J, Rui S, Ernstoff MS, Taback B, Pabla S, Chang R, Lee SJ, Krolewski JJ, Morrison C, Horst B, <strong>Saenger YM, &ldquo;</strong></span><strong><span style="font-size: 14pt; font-family: Calibri, sans-serif; color: #222222; background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; font-weight: normal;">Validation of Melanoma Immune Profile (MIP), a Prognostic Immune Gene Prediction Score for Stage II-III Melanoma,&rdquo;</span></strong> <strong><em><span style="font-size: 14pt; font-family: Calibri, sans-serif; color: #222222; background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; font-weight: normal;">Clinical Cancer Research</span></em></strong><strong><em><span style="font-size: 14pt; font-family: Calibri, sans-serif; color: #222222; background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;">, </span></em></strong><strong><span style="font-size: 14pt; font-family: Calibri, sans-serif; color: #222222; background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; font-weight: normal;">2019 Jan 15</span></strong> <span style="font-size: 14pt; font-family: Calibri, sans-serif;">PMID: 30647081</span></p>
<p class="desc" style="margin: 0in 2pt 0in 0in; background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;"><span style="font-size: 14.0pt; font-family: 'Calibri',sans-serif; mso-ascii-theme-font: minor-latin; mso-hansi-theme-font: minor-latin; mso-bidi-theme-font: minor-latin;">&nbsp;</span></p>
<p class="desc" style="margin: 0in 2pt 0in 0in; background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;"><span style="font-size: 14pt; font-family: Calibri, sans-serif;">Zhao J, Chen AX, Gartrell RD, Silverman A, Aparicio L, Chu T, Bordbar D, Shan D, Samanamud J, Goetz M, Yagamuchi JT, Cloney M, Horbinski C, Lukas RV, Raizer J, Rae AI, Yun J, Canoll P, Bruce JN, <strong>Saenger YM</strong>, Sims P, Iwamoto FB, Sonabend AM, Rabadan, R. &ldquo;Longitudinal genomic study of response to anti-PD-1 immunotherapy in Glioblastoma Multiforme<em>,&rdquo; Nature Medicine 2019 </em>Mar 25(3):462-469 PMID: 30742119</span></p>
<p class="desc" style="margin: 0in 2pt 0in 0in; background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;"><span style="font-size: 14.0pt; font-family: 'Calibri',sans-serif; mso-ascii-theme-font: minor-latin; mso-hansi-theme-font: minor-latin; mso-bidi-theme-font: minor-latin;">&nbsp;</span></p>
<p class="desc" style="margin: 0in 2pt 0in 0in; background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;"><span style="font-size: 14pt; font-family: Calibri, sans-serif;">Gartrell RD, Marks DK, Hart TD, Li G, Davari DR, Wu A, Blake Z, Lu Y, Askin KN, Monod A, Esancy CL, Stack EC, Jia DT, Armenta PM, Fu Y, Izaki D, Taback B, Rabadan R, Kaufman HL, Drake CG, Horst BA, <strong>Saenger YM, &ldquo;</strong>Quantitative Analysis of Immune Infiltrates in Primary Melanoma,&rdquo;<span class="jrnl"> <em>Cancer Immunol Res</em></span><em>.</em> 2018 <span style="background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;">Apr;6(4):481-493</span> PMID: 29467127</span></p>
<p class="desc" style="margin: 0in 2pt 0in 0in; background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;"><span class="docsum-authors"><span style="font-size: 14pt; font-family: Calibri, sans-serif;">&nbsp;</span></span></p>
<p class="desc" style="margin: 0in 2pt 0in 0.25in; text-indent: -0.25in; background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;">&nbsp;</p>
<p class="desc" style="margin: 0in 2pt 0in 0in; background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;"><span class="docsum-authors"><span style="font-size: 14pt; font-family: Calibri, sans-serif;">Gartrell RD, Enzler T, Kim PS, Fullerton BT, Fazlollahi L, Chen AX, Minns HE, Perni S, Weisberg SP, Rizk EM, Wang S, Oh EJ, Guo XV, Chiuzan C, Manji GA, Bates SE, Chabot J, Schrope B, Kluger M, Emond J, Rabad&aacute;n R, Farber D, Remotti HE, Horowitz </span></span><span class="docsum-authors"><span style="font-size: 14pt; font-family: Calibri, sans-serif;">DP,&nbsp;<strong>Saenger YM. </strong></span></span><span style="font-size: 14pt; font-family: Calibri, sans-serif;">Neoadjuvant chemoradiation alters the immune microenvironment in pancreatic ductal adenocarcinoma, <span class="docsum-journal-citation">Oncoimmunology. 2022 May 5. PMID: </span><span style="background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;">35558160</span></span></p>
<p>&nbsp;</p>
<p>&nbsp;</p>

EMR ID

116437

Is Open Scheduling

Off

Norman L. Rosen

https://assets.montefioreeinstein.org/profiles/images/default-profile-blue.svg

First Name

Norman

Last Name

Rosen

NPI

1053492215

Faculty ID

4387

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Male

Email

Phone

Titles

Locations

Education and Trainings

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Elsevier Profile

EMR ID

3442

Is Open Scheduling

Off

Mark A. Ramirez

https://assets.montefioreeinstein.org/profiles/images/physphoto/Ramirez_Mark_MD.jpg

First Name

Mark

Last Name

Ramirez

NPI

1467494336

Faculty ID

3064

CMO Specialties

Clinical Terms

Employment Status

Per Diem

Patient Type

Adult

Department

Languages

Gender

Male

Email

Phone

Titles

Locations

Education and Trainings

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Elsevier Profile

EMR ID

3582

Is Open Scheduling

Off

Joshua P. Raff

https://documentapi-fargate-documentbucket-15qi4tpdvnhlz.s3.amazonaws.com/218/f591cd20-c723-11ee-a272-67239916ef55.jpg

First Name

Joshua

Last Name

Raff

NPI

1689672362

Faculty ID

18177

CMO Specialties

Clinical Terms

Employment Status

Voluntary

Patient Type

Adult

Department

Gender

Male

Email

Phone

Titles

Locations

Education and Trainings

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

EMR ID

4127

Is Open Scheduling

Off

Stuart Packer

https://documentapi-fargate-documentbucket-15qi4tpdvnhlz.s3.amazonaws.com/218/0d90dcb0-3939-11ed-9b41-f32856b0701a.jpg

First Name

Stuart

Last Name

Packer

NPI

1124059621

Faculty ID

13484

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Male

Email

Phone

Titles

Locations

Education and Trainings

Professional Interests

<p>Stuart Packer, MD, is a medical oncologist with extensive experience in treating lung, head and neck, prostate and other types of cancer. After graduating magna cum laude from Case Western Reserve University, Dr. Packer received his medical degree from the State University of New York/Downstate Medical Center. He went on to complete a residency in medicine and fellowship in hematology/medical oncology at Duke University Medical Center. Since then Dr. Packer has held clinical and teaching positions at leading cancer centers, including Memorial Sloan-Kettering Cancer Center, Mount Sinai School of Medicine and Montefiore Einstein Center for Cancer Care.</p>
<p>Dr. Packer&rsquo;s clinical expertise is in medical management of lung cancer, head and neck cancer and prostate cancer. He is director of the melanoma and sarcoma programs at Montefiore Einstein Center for Cancer Care. In addition, Dr. Packer is medical director of Montefiore&rsquo;s Oncology Care Model (OCM), an alternative payment model sponsored by the Centers for Medicare and Medicaid Services and aimed at improving patient care coordination and appropriateness of care.</p>
<p>Dr. Packer is the author or co-author of medical textbook chapter and articles in peer-reviewed journals, including <em>Cancer, Clinical Cancer Research, British Medical Journal</em> and <em>Lung Cancer</em>. He is a member of the American Society of Clinical Oncology and the American Society of Hematology.</p>

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Clinical Focus

Dr. Packer&rsquo;s clinical expertise is in medical management of lung cancer, head and neck cancer and prostate cancer.

Elsevier Profile

EMR ID

5497

Biography

<p>Stuart Packer, MD, is a medical oncologist with extensive experience in treating lung, head and neck, prostate and other types of cancer. After graduating magna cum laude from Case Western Reserve University, Dr. Packer received his medical degree from the State University of New York/Downstate Medical Center. He went on to complete a residency in medicine and fellowship in hematology/medical oncology at Duke University Medical Center. Since then Dr. Packer has held clinical and teaching positions at leading cancer centers, including Memorial Sloan-Kettering Cancer Center, Mount Sinai School of Medicine and Montefiore Einstein Center for Cancer Care.</p><p>Dr. Packer&rsquo;s clinical expertise is in medical management of lung cancer, head and neck cancer and prostate cancer. He is director of the melanoma and sarcoma programs at Montefiore Einstein Center for Cancer Care. In addition, Dr. Packer is medical director of Montefiore's Oncology Care Model (OCM), an alternative payment model sponsored by the Centers for Medicare and Medicaid Services and aimed at improving patient care coordination and appropriateness of care.</p><p>Dr. Packer is the author or co-author of medical textbook chapter and articles in peer-reviewed journals, including <em>Cancer</em>, <em>Clinical Cancer Research</em>, <em>British Medical Journal</em> and <em>Lung Cancer</em>. He is a member of the American Society of Clinical Oncology and the American Society of Hematology.</p>

Is Open Scheduling

Off

Sun Young Oh

https://documentapi-fargate-documentbucket-15qi4tpdvnhlz.s3.amazonaws.com/218/25418200-f8b2-11ec-9cb7-15f799598473.jpg

First Name

Sun Young

Last Name

Oh

NPI

1174887699

Faculty ID

14930

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Female

Email

Phone

Titles

Locations

Education and Trainings

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Clinical Focus

<span style="color:#4d4d4d;font-family:Arial, Helvetica, source-code-pro, Menlo, Monaco, Consolas, 'Courier New', monospace;font-size:16px;background-color:#ffffff;">The clinical focus is on medical oncology and the systemic treatment of breast cancer.</span>

Research Focus

<span style="color:#4d4d4d;font-family:Arial, Helvetica, source-code-pro, Menlo, Monaco, Consolas, 'Courier New', monospace;font-size:16px;background-color:#ffffff;">Dr. Oh&rsquo;s research follows her clinical focus and has been shared through publication in peer-reviewed journals.</span>

Elsevier Profile

EMR ID

55194

Biography

<p>Sun Young Oh, MD, is an Oncologist and Assistant Professor, Oncology and Medicine at Montefiore Einstein. Her clinical focus is on medical oncology and the systemic treatment of breast cancer.</p><p>In 2003, Dr. Oh completed her Doctor of Medicine at Ewha Womans University in Seoul, South Korea. She pursued postdoctoral training in the United States completing her internal medicine internship at Lutheran Medical Center in 2006, her internal medicine residency at Jacobi Medical Center/Albert Einstein College of Medicine in 2008 and her hematology and oncology fellowship at Tufts Medical Center/Tufts University School of Medicine in 2015.</p><p>Dr. Oh&rsquo;s research follows her clinical focus and has been shared through publication in peer-reviewed journals.</p><p>Dr. Oh is board certified in internal medicine, medical oncology and hematology. She is a member of the American Society of Clinical Oncology</p>

Is Open Scheduling

Off

Katharine A. McNeill

https://documentapi-fargate-documentbucket-15qi4tpdvnhlz.s3.amazonaws.com/218/507c4f00-3934-11ed-9b41-f32856b0701a.jpg

First Name

Katharine

Last Name

McNeill

NPI

1598995730

Faculty ID

15494

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Female

Email

Phone

Titles

Locations

Education and Trainings

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Elsevier Profile

EMR ID

1542

Is Open Scheduling

Off